Member Info for Bella6532

The other critical point is upcoming flu vaccinations.
Any Covid treatment will have to also maintain it's safety and efficiency alongside a flu vaccination.

I think we can say this research has already been done when it comes to Interferon Beta 1a so SNG001 again should be further along in that regard if they can cite previous research be it their own or others...

https://pubmed.ncbi.nlm.nih.gov/16380621/
Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a

As mentioned last night, Transcrip worked the Synairgen on their trial and I put it to you they did so to make sure the trial was set up in such a way it met the new FDA approval parameters (particularly the new Covid19 emergency use) and of course those of other regulatory bodies.
https://www.transcrip-partners.com/news/covid-19-developing-drugs-and-biological-products-treatment-or-prevention-background-and-new

Once the results final I's and T's have been dotted and crossed, then Transcrip should be in a position to lodge whatever paperwork is needed (and some form filling/submissions may well have already taken place) to get approvals through quickly.

Sparkle... The licencing deal they struck with AZ could easily be struck again with any one of the big pharma out there and would leave SNG to work on new research projects and at the same time bring in big bucks for basically doing nothing more with SNG001.
A quick Google search will give you the terms of that deal...

'tranScrip’s Regulatory team has worked on all stages of projects ranging from First-in-Man through to submissions for regulatory approval and subsequent variations. tranScrip has extensive experience in exploring creative regulatory strategies with health authorities to streamline the development programmes. Our geographical experience covers, FDA, EMA and PMDA.'

They have several satellite offices including one in Boston.

https://www.transcrip-partners.com/

As already mentioned. Transcript involved in SNG trial..

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment
It's possible to get FDA emergency use approval in a matter of just two days after a completed trial...

Apologies if already posted
https://www-bloomberg-com.cdn.ampproject.org/v/s/www.bloomberg.com/amp/news/articles/2020-07-21/covid-antibodies-fade-rapidly-raising-risk-of-lost-protection?

Richard Marsden, Chief Executive Officer of Synairgen, told Bloomberg TV that "things are moving very quickly" when referring to receiving approval for wide approval of the drug. British authorities have been eager to throw money at any vaccine or cure and have also been willing to fast-track of approvals. Other countries will likely follow the UK in giving a green light for usage if London does so.

Moreover, Marsden said that he is in touch with several larger pharmaceutical companies regarding scaling up the production of the medication. While the large firms may take a cut from SNG's profits, the rapid distribution could help it gain market share. It could also open the door to one of the giants purchasing the Synargien, which is only valued at around £328 million. That seems like a modest sum for a company at the forefront of the worst medical disaster in recent history.

Yes we will still hold our value. If SNG apply for emergency use they will get a local to assist. Guys no worries on this one. There are plenty of licencing deals to be done on the back of assistance...

Happens all the time...they're trying to keep price down to fill their boots...
Nobody trolls a duff share....

They can go for Emergency use...

'Synairgen Plc Chief Executive Officer Richard Marsden discusses the company's experimental drug which in a clinical trial cut the risk of developing the worst symptoms of Covid-19. Synairgen, a tiny pharmaceutical firm born out of a U.K. university, will now enter discussions with the U.S. Food and Drug Administration and the European Medicines Agency, Marsden said in an interview on "Bloomberg Surveillance."'

https://www.bloomberg.com/news/videos/2020-07-21/synairgen-seeks-fda-ema-engagement-on-covid-19-drug-video

'The CEO also said that while “conventional wisdom” may dictate that SNG001 should be used early in the infection cycle, there does not seem to be any link between the length of time before the treatment is administered and differences in outcome, with even late administration of the treatment yielding positive results.

“That’s a really pleasant aspect to this data set”, he said.'

Interesting comment...
A. I wonder if the COPD data lead them to this conclusion.
B. Home Trial good but may not need to wait for the results really...all systems go when these results are finalised...

It's been traded within a fairly strict price width so it might be they are working through a large order before US opens...

43.5m traded today...
A close above on on today's high will bode very well for tomorrow...

For a professor to use the word 'huge'... That in itself is huge.

Eva.. Thanks for your kind post...guess Acacia will find it much easier to offload balance if the still wish to do so...

Surely time is of the essence too.
2nd wave is coming and Govts will be looking for solutions to keep as many people out of hospital as possible. If the hospital trial results give them what they want/need and the medical advisors are happy with them, then it could be introduced as a treatment for certain cases and home trial once outcome known used to support wider population treatment.
Dont under estimate how desperate Govts are right now... This is about keeping people out of hospital and getting them back to work ASAP.. Nothing more.. Nothing less.
It's not about Covid cases.

If the hospital trial is good then sentiments will drive expectation regarding home trial being even better. Its sentiment that will drive the SP ahead of home trial news.
Great advice Eva.. Definitely time for a few cold ones.

Another day like today and Acacia will be done and dusted...

Another day like today and Acacia will be done and dusted...
In

10m to go and getting into the area where one or two big investors could easily pop in and gobble up the lot in one go... Looking at the trading values I suspect they have been worked through into the PI market mostly.